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1. Introduction 
Tumor growth and metastasis depend on neovascularisation, which has been recently 
believed promoted by cancer stem cells (CSCs), a special subpopulation of tumor cells. The 
cancer stem cell theory can be traced back to the first mention by Furth and Kahn in 1937, 
when their results revealed a single leukaemic cell capable of transmitting the systemic 
disease in mice [1]. However, it was not until the 1990s that CSCs were identified and well-
characterized in acute myeloid leukaemia (AML). Among cancer cells isolated from AML 
patients, only a small fraction of them exhibiting the hematopoietic stem cell surface 
phenotype, i.e. CD34+ and CD38-, were capable of initiating leukaemia in mice similar to 
that of the original patient. These cells were then known as SCID leukemia-initiating cells 
with potentials to self-renew, proliferate and differentiate in vivo [2, 3]. Since then, CSCs 
from various types of cancer such as breast cancer and malignant glioma have been well 
characterized, and then the existence of CSCs in solid tumors has been gradually accepted 
[4-10]. The studies promote a common recognition of the accurate definition for CSCs 
reached by an American Association for Cancer Research (AACR) workshop in 2006, that 
CSCs are a small subset within a cancer that constitute a reservoir of self-sustaining cells 
with the exclusive abilities to self-renew and to cause the heterogeneous lineages of cancer 
cells that comprise the tumor [11]. 
Investigation on CSCs provides a new insight into our understanding for tumorigenesis, 
recurrence and metastasis of cancer as well as development of new strategies for cancer 
treatment. Due to up-regulation of drug resistance and anti-apoptotic genes as well as 
greater DNA-repair responses, CSCs are more resistant to chemo- and/or radiotherapies 
than differentiated cancer cells [12-17]. Recent studies suggest that CSCs existing in the 
tumor are highly invasive, indicating their crucial role in invasion and metastasis of cancer 
[18]. Therefore, eradication of CSCs is of great importance in preventing cancer recurrence 
and metastasis. 
The increasing awareness of neovascularization holding a master switch of tumor 
development and progression indicates that vascularization plays a crucial role in the stage 
of tumor progression [19]. It is generally thought that vascularization is initiated by 
microenvironmental changes such as hypoxia followed by tumor outgrowing its blood 
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supply limitation. This process is further promoted by angiogenic factors derived from 
tumor cells and infiltrating inflammatory/immune cells into tumor tissues [20-22]. Tumor 
vasculatures are mainly developed through angiogenesis by sprouting from pre-existing 
vessels and vasculogenesis via recruitment of endothelial progenitor cells (EPCs) [23, 24]. 
Both of the processes are initiated and promoted by angiogenic factors [20, 22, 25] such as 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) 
produced by cancer cells and stromal cells [22, 26, 27]. Interestingly, cancer cells exhibit 
heterogeneity in their production of angiogenic factors. 
CSCs have been more recently identified as initiating cells of tumor neovascularization [28-
33], but many doubts still challenge CSC theory. In this review, we provide the evidence for 
the role of CSCs in tumor vascularization and discuss the potential therapeutic significance 
based on the interaction between CSCs and their vascular niches. 
2. CSCs produce angiogenic factors 
CSCs play a predominant role in tumor angiogenesis through producing high levels of pro-
angiogenic factors. Evidence from our laboratory and others has indicated that CSCs 
produce preferentially higher levels of angiogenic factors, for instance, VEGF and 
interleukin 8 (IL-8). Ponti et al identified a subpopulation of sphere-forming cells with CSC 
properties, named MCF-S, from an established breast carcinoma cell line MCF-7 [28]. It was 
found that MCF-S cells expressed higher levels of VEGF mRNA compared with MCF-7. 
Meanwhile, higher amounts of VEGF protein were measured in the MCF-S culture medium, 
indicating CSCs might possess stronger pro-angiogenic capability than differentiated tumor 
cells. Bao et al found that hypoxia could induce glioma stem cells to produce higher levels of 
angiogenic factor VEGF [29]. CSC-enriched neurospheres derived from the GL261 murine 
glioma cell line and rat glioma cell line C6 express more VEGF compared with adherent, 
CSC-low cultures [30, 31]. Compared with adherent C6 cells, sphere-forming C6 cells 
induced higher levels of proliferation and tubulogenesis of endothelial cells in vitro. 
Accordingly, xenografts derived from sphere-forming C6 cells exhibited increased 
microvessel density and blood perfusion and induced increased mobilization and tumor 
recruitment of bone marrow-derived endothelial progenitor cells (EPCs). When VEGF was 
blocked, all aspects of angiogenesis observed in sphere-forming C6 cells and xenografts, 
including microvessel density, perfusion, EPC mobilization/recruitment, and stimulation of 
endothelial cell activity, were reduced to levels comparable with those observed in either 
adherent C6 cells or their implanted tumors [31]. Furthermore, CSC-enriched CD133+ 
fraction derived from the U87 human glioblastoma cell line and primary human gliomas 
also had a significantly stronger capacity of promoting angiogenesis than the CSC-depleted 
CD133- fraction. Accordingly, CD133+ glioma cells generated highly vascularized tumors 
when implanted in mice, whereas the matched CD133 populations were rarely tumorigenic 
and gave rise to poorly vascularized tumors. The proangiogenic capacity of CD133+ fraction 
was attributable to VEGF activity [29, 32]. The evidence of in vivo pro-angiogenic effects of 
CSCs was further proved by Oka and the colleagues [33]. Transfecting glioma stem cells 
with a retrovirus vector expressing VEGF promoted vascular formation and tumor-
associated hemorrhage. The blood vessels adjacent to and within the tumors derived from 
VEGF-expressing glioma stem cells exhibited much higher density and more complexity of 
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neovascularization. The newly formed vessels had functional walls and lumens when they 
were stained with anti-CD31 antibody and PAS histochemistry demonstrated central 
lumens and new basement membrane. Taken together, VEGF appears to be an important 
mediator for CSC contribution to tumor neovascularization. 
Chemokines and their receptors are believed to be involved in CSCs-mediated production of 
angiogenic factors. For instance, CXCR4, a chemokine receptor that plays an important role 
in tumor angiogenesis, was preferentially expressed in glioma stem cells [16, 34-36]. 
Meanwhile, stromal derived factor-1 (SDF-1) or CXCL12, the sole ligand for CXCR4, can be 
detected in glioma stem cell culture medium, indicating that CXCR4 expressed by glioma 
stem cells can be activated in an autocrine manner. Using a rat aortic ring assay, Salmaggi 
and the colleagues found glioma stem cells induced apparently longer and thinner neo-
vessels compared with control group. They further documented high expression of CXCR4 
and release of CXCL12 by glioma stem cells might be the underlying mechanism [34]. In our 
recent studies, we also found that CD133+ glioma stem cells had significantly higher CXCR4 
mRNA and protein expression levels, as well as higher chemotactic response to its ligand 
CXCL12 as compared to CD133 negative cells [37]. In addition to chemokine receptor 
CXCR4, formylpeptide receptor (FPR), a classic chemoattractant receptor, was also found to 
induce VEGF production by glioma stem cells [32]. This G-protein coupled receptor 
mediates neutrophils to participate in inflammation, and we previously found its promotion 
of tumor growth and invasion through its activation by binding its stimulator from necrotic 
tumor cells. We recently reported this receptor expressed on glioma stem cells was 
functional and its activation promotes stem cells production of angiogenic factors such as 
VEGF and IL-8/CXCL8, resulting in initiation of angiogenesis. When transplanting human 
CSCs into nude mice, the CSCs produced in situ angiogenic factors and generated a higher 
density of microvessels to promote tumor growth. These results strongly suggest that 
chemoattractants and their receptors, at least in part, are among the major signals to 
promote CSC-mediated tumor angiogenesis by stimulating VEGF production. 
Although a greater contribution of CSCs to tumor angiogenesis than their differentiated 
counterparts within a tumor has been supported by many studies, contradictory 
phenomenons have also been observed. Salmaggi et al found non-sphere-forming cells from 
GBM could induce more vessels than glioma stem cells using the aortic ring assay. They 
observed that the pro-angiogenic capacity varied among different passages of glioma stem 
cells. Pro-angiogenic ability of glioma stem cells increased after serial passages in culture 
concomitant with elevated VEGF and CXCL12 production [34]. Consequently, VEGF mRNA 
was increased in the secondary tumor spheres acquired from primary tumorospheres of 
xenografts [34]. Recently, Sakariassen et al observed angiogenesis-dependent and 
angiogenesis-independent patterns in glioma stem cell-derived xenografts [38]. Great 
differences were seen in gene expression profiles and signaling pathways between the 
glioma stem cells with two different tumor generation patterns. These results indicate that 
CSCs are actually heterogeneous in their contribution to neovascularization. Further studies 
are still needed to elucidate the exact subclones preferentially contributing to tumor 
angiogenesis for more effective targeting to angiogenesis-initiating stem cells. 
3. CSCs transdifferentiate into endothelial cells 
Endothelial cells (ECs) not only interact with cancer cells through aberrant growth factors, 
but also share genetic abnormality with cancer cells, which might suggest a link in their 
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common origin [39-41]. Streubel et al investigated 27 cases of lymphoma and found 15% to 
85% of the microvascular ECs harbored the same lymphoma-specific genetic aberrations. In 
vitro assays also showed that the ECs isolated from primary human lymphoma presented 
the lymphoma-specific genetic aberrations [39]. In multiple myeloma patients with the 
13q14 deletion, a significant proportion of circulating ECs carried the same chromosome 
aberration as the neoplastic plasma cells, and presented the same immunoglobulin gene 
rearrangement as multiple myeloma plasma cells. In addition, most circulating ECs 
presented EPC features as they expressed CD133, a marker gradually lost during 
endothelial differentiation and absent on mature ECs [40]. Renal tumor-derived ECs but not 
normal ECs expressed paired-box 2 (Pax2) proteins and mRNA, which were restricted to the 
developing kidney in the embryo [41]. These results suggest that cancer cells and ECs might 
derive from common multipotent progenitor cells, or possibly CSCs. 
More evidence supports that CSCs might generate or transdifferentiate into ECs for 
neovascularization. Pezzolo et al investigated the origin of the microvascular ECs in MYCN-
amplified nephroblastoma and found that 20%-78% of the ECs identified by CD105 
expression exhibited amplification of the oncogene MYCN, the tumor marker of this tumor 
at stage 3 and 4. This finding strongly implicates the possible cancer cell origin of ECs in 
MYCN amplification nephroblastoma. Furthermore, microvessels formed by the ECs were 
functional because they contained erythrocytes and were covered with a layer of pericytes. 
They further studied a cell line HTLA-230 from human stage 4 nephroblastoma with MYCN 
amplification and injected the cells into immunodeficient mice to investigate the origin of 
ECs in the xenografts. It was found that the xenografts contained approximately 80% of 
human ECs and 20% murine ECs, suggesting the nephroblastoma cells directly 
transdifferentiating to tumor ECs [42, 43].  
More direct evidence of the potential transdifferentiation of CSCs to ECs has been reported 
in recent years. In a study with the injecting fluorescence-labeled human cutaneous 
metastatic melanoma cells into the ischemic hind limbs of nude mice, it was found that after 
five days, the vessels consisted of human melanoma-derived cells adjacent to and 
overlapping with mouse ECs in a linear arrangement were formed and provided blood for 
the ischemic limbs [44]. A CD133+ cell population, which is negative for the endothelial 
marker CD34, but positive for the renal embryonic marker Pax-2, derived from human renal 
carcinomas was also able to differentiate into ECs. When injected subcutaneously in SCID 
mice, they formed functional vessels which integrated with the mouse vasculature. Among 
the tumor vasculature, vessels of human origin accounted for 85% and were mainly located 
within the tumors [45]. Kusumbe et al isolated a non-tumorigenic CD133+ population in 
ovarian cancer and termed them as endothelial stem cells (EnSCs) based on their capacity of 
differentiating into ECs. A unique feature of these EnSCs is the continual expression of the 
surface molecule CD44 at all the steps of the hierarchy [46]. In the two reports, the authors 
did not detect the cellular karyotypes, thus we cannot know whether these cells are normal 
or abnormal in their phenotype. However, the expression of Pax-2 or CD44 suggested that 
they are not hematopoietic cells or endothelial cells. As they were isolated from tumors, it 
can be hypothesized that this CD133+ population might be a committed lineage that derived 
from CSCs and could differentiate into ECs but not tumor cells. This was confirmed by Shen 
and his colleagues who found precancerous stem cells (pCSCs), representing the early stage 
of developing CSCs, can not only initiate tumors but also generate most of the tumor 
vasculature [47, 48]. More recently, Bussolati and the colleagues isolated and cloned a 
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population of breast CSCs, which were able to differentiate into the endothelial lineage 
acquiring endothelial markers and the ability to organize in Matrigel into capillary-like 
structures when cultured in the presence of VEGF. The capacity of in vivo endothelial 
differentiation was proven by vessels of human origin in the transplanted tumors, formed 
by these cells [49]. Evidence from the studies of CSCs in human renal carcinomas and 
ovarian cancers also confirmed the capacity of CSCs to transdifferentiate into endothelial 
cells. CD105+ tumor-initiating cells isolated from human renal carcinomas acquired an 
endothelial phenotype when cultured in endothelial differentiating medium containing 
VEGF and generated ECs of human origin in the central of SCID xenografts [50]. Ovarian 
cancer cells with stem-like properties can also transdifferentiate into ECs both in intro and in 
vivo. Interestingly, this transdifferentiating process was shown to be VEGF-independent, 
but IKK┚-dependent [51], suggesting either VEGF-dependent or VEGF-independent 
mechanisms are involved in the trans-endothelial differentiation of CSCs. 
4. CSCs contribute to vasculogenic mimicry 
It is a widely-accepted paradigm that tumor vasculature is mostly composed of non-
malignant endothelial cells originating from pre-existing blood vessels sprouting into tumor 
mass and recruitment of circulating endothelial progenitor cells (EPCs) mediated by 
angiogenic growth factors produced by host or tumor cells [52]. However, classical patterns 
of angiogenesis and vasculogenesis have been challenged by clinical investigation of tumor 
tissues because tumor vasculature can also be formed by vasculogenic mimicry (VM) [53]. 
VM is a structure through which tumor tissues nourish themselves, mimicking the pattern 
of embryonic vascular network. Tumor cells with high degree of differentiation plasticity 
may contribute to the de novo formation of tumor cell-lined blood channels [54]. These 
extracellular matrix-rich vasculogenic tumor cell networks were shown to conduct fluid. An 
interesting observation was that VM was most frequently observed in the boundary regions 
between the tumor and surrounding normal tissues [55]. Thus, VM may also play a role in 
tumor invasion by supplying immediate nutrition. Furthermore, angiogenesis inhibitors 
abrogate new vessels formed by human vascular endothelial cells in vitro, while under the 
same conditions did not affect tumor cell tuber network formation, and even induced the 
formation of VM as an escape route by tumor tissue for progressive growth [56]. Therefore, 
VM might represent an important survival mechanism contributing to the failure of current 
antiangiogenic therapy aimed to fully deprive tumors of blood supply [57]. Despite its 
clinical importance, the cellular and molecular events underlying the formation of VM are 
not well understood. Recent discovery of cancer stem cells (CSCs), with the capability of 
self-renewal and multi-potency of differentiation, has stimulated great interest in re-
defining tumor initiation and progression [58]. However, whether CSC theory can be 
applied to the formation of tumor cell-associated vasculogenesis, especially in respect to 
VM, remains unclear. Based on the present findings that most vessels in tumor may be 
originated from tumor cell themselves through the process of vasculogenesis [59], as well as 
that CSCs were able to serve as precursors of tumor stromal components such as tumor 
vasculogenic stem/progenitor cells (TVPCs) regulated by signals from 
microenvironment/niche surrounding these cells [60], it is plausible that CSC compartment 
of a tumor may be involved in VM formation, by differentiating/transdifferentiating into 
endothelial-like cells. Such a potential function of CSCs might represent one of the 
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mechanisms by which CSCs initiate neoplastic formation and promote tumor progression 
[61]. In this review, we will focus on the possible role of CSCs in VM formation and how the 
niche surrounding CSCs may affect VM formation.  
4.1 Current understanding of tumor VM 
In 1999, Maniotis et al. first described VM in aggressive melanoma with tumor cells 
expressing endothelial phenotype pasted on the surface of the basement membrane in 
tubular structure [62]. VM in the tumor mass is connected with host vessels for blood 
supply. Periodic acid-Schiff (PAS) staining is commonly utilized to identify VM. PAS-
positive channels were lined externally by tumor cells, lacking an inner lining of endothelial 
cells [63]. Although the functionality and contribution of VM channels to circulation were 
criticized initially, Frenkel et al. [64] demonstrated that blood circulated in VM tube with 
laser scanning confocal angiography in a patient with a choroidal melanoma. Therefore, VM 
is a new pattern that provides tumor mass with nutrition independent of conventional 
angiogenesis and vasculogenesis. Zhang et al. [65] proposed three-stage blood supply 
patterns in tumor including VM, mosaic vessels (MV) and endothelium-dependent vessels, 
in which all three patterns provide blood supply. The model proposes that VM is the 
dominant blood supply pattern in the early stage characterized by rapid tumor growth. 
Consequently, to maintain expansion of tumor mass, endothelial cells differentiate and 
proliferate, and the mosaic vessels appeared as a transitional pattern. Endothelium-
dependent vessels then replace VM and mosaic vessels to become a major pattern of blood 
supply in the late stage of tumor growth. Thus, VM may be the main source of blood supply 
at the early stage of rapid tumor growth, when endothelium-dependent vessels, which 
require the sprouting and recruitment of endothelial cells, are insufficient to sustain 
aggressive tumor growth. Based on PAS staining, VM are divided into seven categories: 
straight channels, parallel straight pattern, parallel straight pattern with cross link, arcs (not 
closed), arcs with branching, closed loops, and networks [66].  
VM has been detected in melanoma, breast carcinoma, prostate carcinoma, ovarian 
carcinoma, astrocytoma, and Ewing sarcoma, etc.[67-70]. Microarray analysis indicates that 
VM-positive tumor cells of aggressive melanoma expresses elevated levels of genes 
associated with undifferentiated embryonic-like phenotype [54]. Intra-peritoneally 
implantation of human ovarian cancer cell line SKOV3ip showed that the cells, expressing 
CD31 and Factor VIII of vascular epithelial markers, had plasticity to engage in VM 
formation in vivo [71]. These findings suggest that the plasticity of cancer cells enable them 
to mimic the activities of endothelial cells and participate in the process of VM formation. 
Recent findings of “plastic” endothelial-like phenotype of tumor cells provide additional 
evidence for the role of tumor cells in VM formation.  
There are striking parallels between tumor cells and stem cells: tumors and normal tissue 
are comprised of phenotypically heterogeneous cell populations, and many characteristics 
of stem cells, for example, stem cell plasticity, which is also pertinent to tumor growth [72]. 
Cellular plasticity in stem cells may facilitate the formation of primary vascular network 
during embryonic development. Mesodermal progenitor cells differentiate in situ into 
endothelial cells that are organized into a primitive network to supply nutrition for the 
developing early embryo [73]. The subsequent remodeling of vascular network into more 
complex vasculature appears through the process of angiogenesis. These processes are 
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similar to the formation of tumor vasculature and the plasticity of tumor cells may be 
important for the formation of VM. 
4.2 Differentiation plasticity of CSCs and VM formation 
CSCs are functionally defined by their capacity to regenerate tumors in xenograft mouse 
models [74, 75]. Similar to normal stem cells, CSCs can reproduce the heterogeneous 
phenotype of the parental cancer from which they are derived in transplantation, reflecting 
the multipotent differentiation capacity of CSCs. Plasticity defines the capacity of stem cells 
to differentiate or transdifferentiate into many cell types [76]. During development, 
multilineage differentiation plasticity is one of the characteristics of embryonic stem cells 
(ESC) [77]. CSCs are characterized by their stem/progenitor properties: self-renewal and the 
capability of differentiation into heterogeneous tumor cell populations [11]. Therefore, the 
differentiation plasticity of normal stem cells is also a similar property of CSCs. Bian et al. 
proposed a concept of CSC plasticity (CSCP) in which CSCs possess inducible and reversible 
properties in self-renewal, multipotent differentiation and invasion. For CSCs, 
differentiation plasticity refers to the ability of tumor cells to give rise to phenotypically 
diverse populations including non-tumorigenic cancer cells and stromal cells. In fact, 
aggressive melanoma cells forming VM appear to express genes relevant to multiple cellular 
phenotypes and stem cells including epithelial, endothelial, muscle, neuronal, and other cell 
types. The multipotent, plastic, and embryonic-like phenotype of these melanoma cells has 
also been considered as a defined property of putative malignant melanoma stem cells 
(MMSCs) [78]. Therefore, melanoma stem cells possess the differentiation plasticity 
(transdifferentiation) and this property may play a critical role in VM. Recently, a 
transdifferentiative capability has been demonstrated for bone marrow macrophages, which 
form VM in multiple myeloma. Thus, at least in melanoma, VM channel was believed to be 
due to the transdifferentiation of MMSC subset inside the aggressive tumor. In a study of 
breast cancer, CSCs in endothelial differentiating medium were capable of differentiating 
into endothelial cells, which formed both vessels and tumor [79]. It is conceivable that 
CSCs/tumor initiating stem cells of solid tumor have the competence of differentiation 
plasticity, which further supports the hypothesis that CSCs/tumor initiating stem cells 
possess the properties of normal stem cells important for tumor growth and vascularization.  
Evidence for direct involvement of tumor cells in VM was also obtained in human 
neuroblastoma (NB) [59]. Microvessels formed by MYCN-amplified NB tumor cells 
displayed an open lumen and consistently contained RBCs, indicating that these vessels 
were functional. Moreover, these tumor cell-derived vascular endothelial-like cells were 
different from normal endothelial cells in phenotype and function [59]. Although the study 
only tested MYNC-amplified tumor cells, it is possible that formation of tumor-derived 
endothelial cells is a characteristic feature of a subset of cells in neuroblastoma. In addition 
to neuroblastoma, tumor-associated endothelial microvessels are also found in human B-cell 
lymphomas and multiple myeloma [80]. It is also hypothesized  that precancerous stem cells 
(pCSCs) representing the early stage of developing CSCs may serve as tumor vasculogenic 
progenitor cells (TVPCs) capable of differentiating into tumor vasculogenic endothelial cells 
[60]. Based on observations in animal models as well as human tumor xenografts, a model 
for pCSC or CSC participation in tumor vasculature formation was proposed, in which 
firstly, CSCs and their progenies aggregate to form a mass in tumorigenic 
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microenvironment; secondly, with the extension of aggregates, a CSC subset with properties 
of tumor vasculogenic endothelial cells differentiate/transdifferentiate and line up to form 
branching lumens and tubes, resembling vascular network; and finally, the tubes extend and 
elongate, and the vasculature merges with host vessels from sprouting of pre-existing blood 
vessels and recruitment of circulating endothelial progenitor cells surrounding tumor mass. 
This model emphasizes the intrinsic property of CSCs in tumor vasculogenesis, and explains 
why most anti-angiogenic clinical trials fail to completely eradicate tumor, because the 
drugs tested may be effective on normal endothelial cells but not endothelial-like cells 
derived from CSCs [81]. Our recent studies also observed that glioma stem cells (GSCs), 
isolated from primary glioma sample [82] and a human glioblastoma cell line U87 [83], are 
capable of multipotent differentiation. In stem cell medium, such GSCs form spheroids, and 
in differentiation conditions they form tumor masses that contain fissure and branching 
lumen as revealed by electron microscope. These novel findings support the premise that 
VM positive tumor cells possess a multipotent phenotype and such cells with embryonic 
stem cell-like properties should be considered as antiangiogenic therapeutics.  
4.3 Microenvironmental niche as a regulator of VM formation 
The vasculogenesis and/or angiogenesis, which are necessary for tumor development and 
progression, involve the interaction of tumor and other cell types in the 
microenvironment or niche [84]. A pertinent role of the microenvironment in VM 
formation has been demonstrated in melanoma [85]. Collagen matrices preconditioned by 
aggressive melanoma cells capable of forming VM primed the lesser aggressive melanoma 
cells, which are initially unable to form VM, to express vasculogenic genes and to form 
VM in vitro. These observations illustrate the remarkable influence of microenvironment 
on the phenotype of tumor cells and provide a new perspective for the formation of VM, 
in which factors secreted by tumor cells or other niche components play a critical role in 
cancer cell plasticity, including dedifferentiation and transdifferentiation. In addition, the 
microenvironmental niche has been demonstrated to support normal stem cells in early 
co-culture and transplantation studies [86]. One of the mechanisms by which 
microenvironmental niche determines normal stem cell fate is the control of symmetric 
(producing two identical daughter cells) versus asymmetric (producing one identical and 
one differentiated cell) division [87]. Cancer stem cells, like normal stem cells, also depend 
on interaction with physiologically differentiated cell types or on non-tumorigenic cancer 
cell populations in the same tumor microenvironment to sustain their features and 
destiny [88]. Tumor environment creates a niche favoring the survival, proliferation, and 
differentiation of CSCs. CSCs utilize a specialized microenvironment/niche termed tumor 
stroma, consisted of a combination of different cell lineages, i.e. epithelial, vascular, fat, 
glial, fibroblast, and immune cells along with extracellular matrix, enzymes, and other 
secreted molecules produced by these cells [89]. It has been demonstrated that endothelial 
cells surrounding CSCs appear to directly generate specific microvasculature niche 
and/or secrete factors that promote the formation and/or maintenance of brain CSCs [90]. 
Critical signaling molecules, such as bone morphogenic proteins (BMPs) derived from the 
niche that govern embryonic vascular development, have been linked to melanoma cell-
driven vasculogenesis, i.e. VM [94]. In human glioblastomas, BMP4-BMPR1a signaling 
pathway regulates the differentiation and proliferation of CSC population [92, 93]. Based 
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on these findings, it is plausible that the niche surrounding CSCs controls the 
differentiation plasticity of CSCs, which is responsible for tumor vasculogenesis including 
VM formation.  
In addition to being conditioned by niche components, CSCs may also reciprocally influence 
the niche through secretion of autocrine and/or paracrine factors or through direct cell-cell 
contact to benefit the maintenance of their stemness including self-renewal, multipotent 
differentiation, and tumor-initiation. We and others have suggested that CSCs from U87 cell 
line and primary human brain tumors secrete higher levels of endothelial growth factor 
(VEGF) than their non-tumorigenic counterpart cells that promoted the formation of tumor 
blood vessels [94, 29]. In breast cancer model, VEGF induces CSCs to express endothelial 
markers in vitro and incorporate in tumor vasculature in vivo [79]. Accumulating evidence 
shows in addition to vascular endothelial (VE)-cadherin, laminin 5┛2 chain, and VEGF 
receptor (R)-2, angiogenic factors, including VEGF, angiogenin-1, and ephrinA1, also play a 
critical role in the formation of VM by tumor cells [95]. In healthy individuals, stimulation 
by VEGF, cells of the monocyte lineage (another mesodermal-derived cell) display an 
endothelial phenotype and form a functional capillary-like mesh permeable by blood cells, 
recapitulating embryonic vasculogenesis. VEGF also stimulated macrophages of a patient 
with active multiple myeloma to undergo phenotypic and functional adaptation, expressing 
markers of endothelial cells, i.e. VE-cadherin, VEGFR-2, and FVIII-RA, retained their own 
CD14 and CD68 markers, and these cells can form vessel-like structures on the Matrigel 
surface. Therefore, VEGF can induce macrophages to transdiferentiate into endothelial-like 
cells to form VM, which functionally, phenotypically and morphologically are similar to 
endothelial cells, yet maintain the expression of macrophage markers. Thus, VEGF in the 
niche, which may be derived mainly from CSCs, directly influences the phenotype of CSCs 
and promotes CSCs-associated VM formation. 
There are three factors determining the formation of VM channel: the plasticity of VM-
associated tumor cells, remodeling of extracellular matrix, and the connection of VM with 
host microcirculation [96]. The remodeling of extracellular matrix provides the space needed 
for VM and is regulated by matrix metalloproteinases (MMP) [97]. Matrix MMP-9 and 
MMP-2 play a critical role during the formation of VM in aggressive melanoma. Our recent 
study showed that the expression of MMP-9 and MMP-2 is up-regulated in glioma stem 
cells (GSCs) derived from U87 cell line [98]. The formation of VM also involves migration of 
VM-derived tumor cells. We observed that migration associated molecules, including two 
G-protein coupled chemoattractant receptors formylpeptide receptor (FPR) and CXC 
chemokine receptor-4 (CXCR4) were over-expressed in GSCs isolated from human 
glioblastoma and U87 cell line [84, 37]. FPR and CXCR4 expressed on GSCs, when activated 
by corresponding agonists, mediate directional migration, calcium mobilization, and 
production of VEGF by GSCs. Our recent observations further suggest that activation of 
CXCR4 on GSCs elicits phosphoinositide 3-kinase (PI3K) pathway which is an important 
regulator of VM through MMP-2 [99]. The relationship between CSCs and VM formation 
through stimulatory signals in the niche is important for differentiation plasticity of CSCs. 
Based on the existing observations, it is conceivable that CSCs take part in the VM formation 
through autocrine and/or paracrine manner thereby establishing a vessel niche suitable to 
protect and nourish CSCs. Therefore, VM-targeted therapies should be a new strategy 
aimed at eliminating CSCs.  
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4.4 VM-targeted therapeutic strategy: new perspectives  
CSCs are considered as the root of tumor initiation, metastasis, and reoccurrence. If CSCs 
are proven to be critical for VM formation, there will be significant implications in the 
design of novel anti-tumor therapies. As discussed earlier, VM is the dominant blood 
supply pattern in the early stage of tumor formation and CSCs are capable of 
differentiating/transdifferentiating and lining up to form branching lumens and tubes, a 
process resembling the formation of VM. Traditional anti-angiogenesis drugs, such as 
angiostatin and endostatin, which target normal endothelial cells, have little effect on VM 
due to the absence of normal endothelial cells [100]. In contrast, VEGF-specific inhibitor 
Bevacizumab can conspicuously decrease the number of self-renewing cancer cells from 
orthotopic models of medulloblastoma and glioma, resulting in tumor growth arrest. Direct 
evidence was obtained from aggressive melanoma in that LY294002, a specific inhibitor of 
PI3K, inhibited the ability of undifferentiated embryonic melanoma cells to engage in VM 
on three-dimensional type I collagen matrices [100]. Furthermore, the unique structure of 
VM channels, in which tumor cell line up the inner surface, directly exposes tumor cells to 
blood vessel and facilitates the metastasis of tumor cells. VM frequently is seen in the 
regions between the tumor and surrounding normal tissues, and its appearance in tumor is 
associated with poor prognosis in clinical patients. Therefore, VM-targeted therapies may 
destroy the niche that maintains CSCs, block the metastasis passage of tumor cells, and 
reduce the recurrence of cancer.  
5. Conclusion 
Based on these findings, we conclude that CSCs might initiate and promote 
neovascularization at the early stage of tumor tumorigenesis and progression. There are at 
least three potential mechanisms involved in this process: (1) CSCs induce 
neovascularization through secreting VEGF, which is further induced by hypoxia or 
activation of chemokine receptors; (2) CSCs might participate in angiogenesis through 
transdifferentiating into endothelial cells and/or endothelial progenitor cells; (3) CSCs could 
generate cells that form vasculogenic mimicry and provide nutrition and oxygen directly to 
the tumor mass (Figure 1). On the contrary, the tumor vasculature nourishes CSCs and 
maintains their survival and characteristics of “stemness”. 
Cancer stem cell hypothesis requires elimination of CSCs for more effective treatment of 
cancer. If CSCs exclusively generate heterogeneous tumor cells, elimination of these cells 
will result in arrested tumor growth and eventual eradication. The fact that CSCs contribute 
greatly to tumor neovascularization indicates that restraint of CSCs would impair tumor 
vessels. On the other hand, vascular niches support self-renewal, proliferation and 
differentiation of CSCs, and protect CSCs from chemo- and radiotherapies [90, 101, 102], 
suggesting the necessity to interfere or deplete vascular niches of CSCs. Anti-angiogenic 
drugs indeed reduced markedly the MVD in xenografts and arrested tumor growth [103, 
104]. Thus, a combination of targeting CSCs and their vascular niche will provide more 
effective therapy for tumor treatment. Furthermore, differentiation induction strategy 
targeting the poor-differentiated CSCs may also facilitate cancer treatment [105]. However, 
there is a long way to go for developing the methods targeting CSCs and their vascular 
niche to treat cancers. 
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Fig. 1. Proposed mechanism of cancer stem cells (CSCs) in tumor neovascularization. CSCs 
self-renew and generate cancer cells (A) as well as VM-forming cells (B). The VM-forming 
cells can form functional lumens, incorporating with the endothelial cells either from 
transdifferentiation of CSCs or sprouting of endothelial cells from pre-existing vessels 
(known as angiogenesis), provide blood and nutrition for the tumor mass (C and D). 
Furthermore, proangiogenic factors produced by CSCs and cancer cells promote recruitment 
of circulating EPCs to the tumor tissue and integration into tumor vessels, forming new 
microvessels known as vasculogenesis. 
6. References 
Furth, J., & Kahn, M. (1937). The transmission of leukaemia of mice with a single cell. Am J 
Cancer, 31, 276-282. 
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., et al. (1994). 
A cell initiating human acute myeloid leukaemia after transplantation into SCID 
mice. Nature, 367(6464), 645-648. 
Bonnet, D., & Dick, J.E. (1997). Human acute myeloid leukaemia is organized as a hierarchy 
that originates from a primitive hematopoietic cell. Nat Med, 3(7), 730-737.  
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
252 
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., & Clarke, M.F. (2003). 
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 
USA, 100(7), 3983-3988.   
Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., et al. (2007). Identification 
of pancreatic cancer stem cells. Cancer Res, 67(3), 1030-1037. 
Fang, D., Nguyen, T.K., Leishear, K., Finko, R., Kulp, A.N., Hotz, S., et al. (2005). A 
tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res, 
65(20), 9328-9337. 
Collins, A.T., Berry, P.A., Hyde, C., Stower, M.J., & Maitland, N.J. (2005). Prospective 
identification of tumorigenic prostate cancer stem cells. Cancer Res, 65(23), 10946-
10951. 
Prince, M.E., Sivanandan, R., Kaczorowski, A., Wolf, G.T., Kaplan, M.J., Dalerba, P., et al. 
(2007). Identification of a subpopulation of cells with cancer stem cell properties in 
head and neck squamous cell carcinoma. Proc Natl Acad Sci USA, 104(3), 973-978. 
Dalerba, P., Dylla, S.J., Park, I.K., Liu, R., Wang, X., Cho, R.W., et al. (2007). Phenotypic 
characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA, 
104(24), 10158-10163. 
O’Brien, C.A., Pollett, A., Gallinger, S., & Dick, J.E. (2007). A human colon cancer cell 
capable of initiating tumour growth in immunodeficient mice. Nature, 445(7123), 
106-110. 
Clarke, M.F., Dick, J.E., Dirks, P.B., Eaves, C.J., Jamieson, C.H., Jones, D.L., et al. (2006). 
Cancer stem cells-perspectives on current status and future directions: AACR 
workshop on cancer stem cells. Cancer Res, 66 (19), 9339-9344. 
Dean, M., Fojo, T., & Bates, S. (2005). Tumour stem cells and drug resistance. Nat Rev 
Cancer, 5(4), 275-284. 
Chalmersa, A.J. (2007). Radioresistant glioma stem cells-therapeutic obstacle or promising 
target? DNA Repair, 6(9), 1391-1394.   
Eramo, A., Ricci-Vitiani, R., Zeuner, A., Pallini, R., Lotti, F., Sette, G., et al. (2006). 
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ, 13(7), 1238-
1241.  
Hirschmann-Jax, C., Foster, A.E., Wulf, G.G., Nuchtern, J.G., Jax, T.W., Gobel, U., et al. 
(2004). A distinct ‘‘side population’’ of cells with high drug efflux capacity in 
human tumor cells. Proc Natl Acad Sci USA, 101(39), 14228-14233. 
Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I.R., et al. (2006). Analysis of gene 
expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mole 
Cancer, 5, 67. 
Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., et al. (2006). Glioma 
stem cells promote radioresistance by preferential activation of the DNA damage 
response. Nature, 444(7120), 756-760. 
Sheridan, C., Kishimoto, H., Fuchs, R.K., Mehrotra, S., Bhat-Nakshatri, P., Turner, CH., et al. 
(2006). CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an 
early step necessary for metastasis. Breast Cancer Res, 8(5), R59. 
www.intechopen.com
Cancer Stem Cells Promote Tumor Neovascularization   
 
253 
Narazaki, M., & Tosato G. (2006). Tumor cell populations differ in angiogenic activity: a 
model system for spontaneous angiogenic switch can tell us why. J Natl Cancer 
Inst, 98(5), 294-295. 
Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic 
switch during tumorigenesis. Cell, 86(3), 353-364.   
Greenblatt. M., & Shubik. P. (1968). Tumor angiogenesis: transfilter diffusion studies in the 
hamster by the transparent chamber technique. J Natl Cancer Inst, 41(1), 111-124.  
Folkman, J., & Klagsbrun. M. (1987). Angiogenic factors. Science, 235 (4787), 442-447. 
Fischer, I., Gagner, J.P., Law, M., Newcomb, E.W., & Zagzag, D. (2005). Angiogenesis in 
gliomas: biology and molecular pathophysiology. Brain pathol, 15(4), 297-310. 
Komarovaa, N.L., & Mironov, V. (2005). On the role of endothelial progenitor cells in tumor 
neovascularization. J Theor Biol, 235 (3), 338-349. 
Bian, X.W., Chen, J.H., Jiang, X.F., Bai, J.S., Wang, Q.L., & Zhang, X. (2004). Angiogenesis as 
an immunopharmacologic target in inflammation and cancer. Int 
Immunopharmacol, 4(12), 1537-1547. 
Gilad, A.A., Israely, T., Dafni, H., Meir, G., Cohen, B., & Neeman, M. (2005). Functional and 
molecular mapping of uncoupling between vascular permeability and loss of 
vascular maturation in ovarian carcinoma xenografts: the role of stroma cells in 
tumor angiogenesis. Int J Cancer, 117(2), 202-211. 
Saarinen, N.M., Abrahamsson, A., & Dabrosin, C. (2010). Estrogen-induced angiogenic factors 
derived from stromal and cancer cells are differently regulated by enterolactone and 
genistein in human breast cancer in vivo. Int J Cancer, 127(3), 737-745 
Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D., et al. (2005). 
Isolation and in vitro propagation of tumorigenic breast cancer cells with 
stem/progenitor cell properties. Cancer Res, 65(13), 5506-5511. 
Bao, S., Wu, Q., Sathornsumetee, S., Hao, Y., Li, Z., Hjelmeland, A.B., et al. (2006). Stem cell-
like glioma cells promote tumor angiogenesis through vascular endothelial growth 
factor. Cancer Res, 66(16), 7843-7848. 
Pellegatta, S., Poliani, P.L., Corno, D., Menghi, F., Ghielmetti, F., Suarez-Merino, B., et al. 
(2006). Neurospheres enriched in cancer stem-like cells are highly effective in 
eliciting a dendritic cell-mediated immune response against malignant gliomas. 
Cancer Res, 66(21), 10247-10252. 
Folkins, C., Shaked, Y., Man, S., Tang, T., Lee, C.R., Zhu, Z., et al. (2009). Glioma tumor stem 
cell-like cells promote tumor angiogenesis and vasculogenesis via vascular 
endothelial growth factor and stromal-derived factor 1. Cancer Res, 69(18), 7243-7251. 
Yao, X.H., Ping, Y.F., Chen, J.H., Xu, C.P., Chen, D.L., Zhang, R., et al. (2008). Glioblastoma 
stem cells produce vascular endothelial growth factor by activation of a G-protein 
coupled formlpeptide receptor FPR. J Pathol, 215(4), 369-376. 
Oka, N., Soeda, A., Inagaki, A., Onodera, M., Maruyama, H., Hara, A., et al. (2007). VEGF 
promotes tumorigenesis and angiogenesis or human glioblastoma stem cells. 
Biochem Biophys Res Commun, 360(3), 553-559. 
Salmaggi, A., Bolardi, A., Gelati, M., Russo, A., Calatozzolo, C., Ciusani, E., et al. (2006). 
Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
254 
with angiogenic potential and enhanced multidrug resistance phenotype. Glia, 
54(8), 850-860. 
Ehtesham, M., Mapara, K.Y., Stevenson, C.B., & Thompson, R.C. (2009). CXCR4 mediates 
the proliferation of glioblastoma progenitor cells. Cancer Lett, 274(2), 305-312. 
Krohn, A., Song, Y.H., Muehlberg, F., Droll, L., Beckmann, C., & Alt, E. (2009).CXCR4 
receptor positive spheroid forming cells are responsible for tumor invasion in vitro. 
Cancer Lett, 280(1), 65-71. 
Ping, Y.F., Yao, X.H., Bian, X.W., Chen, J.H., Zhang, R., Yi, L., et al. (2007). Activation of 
CXCR4 in human glioma stem cells promotes tumor angiogenesis. Zhonghua Bing 
Li Xue Za Zhi. 36(3),179-183.  
Sakariassen, P., Prestegarden, L., Wang, J., Skaftnesmo, K.O., Mahesparan, R., Molthoff, C., 
et al. (2006). Angiogenesis-independent tumor growth mediated by stem-like 
cancer cells. Proc Natl Acad Sci USA, 103(44), 16466-16471. 
Streubel, B., Chott, A., Huber, D., Exner, M., Jager, U., Wagner, O., et al. (2004). Lymphoma-
specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. 
N Engl J Med, 351(3), 250-259. 
Rigolin, G.M., Fraulini, C., Ciccone, M., Mauro, E., Bugli, A.M., De Angeli, C., et al. (2006). 
Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. 
Blood, 107(6), 2531- 2535.  
Fonsato, V., Buttiglieri, S., Deregibus, M.C., Puntorieri, V., Bussolati, B., & Camussi, G. 
(2006). Expression of Pax2 in human renal tumor-derived endothelial cells sustains 
apoptosis resistance and angiogenesis. Am J Pathol,168(2),706-713. 
Pezzolo, A., Parodi, F., Corrias, M.V., Cinti, R., Gambini, C., & Pistoia, V. (2007).Tumor 
origin of endothelial cells in human neuroblastoma. J Clin Oncol, 25(4), 376-383. 
Ribatti, D., Nico, B., Pezzolo, A., Vacca, A., Meazza, R., Cinti, R., et al. (2006). Angiogenesis 
in a human neuroblastoma xenograft model: mechanisms and inhibition by tumor-
derived interferon-gamma. Br J Cancer, 94(12), 1845-1852. 
Hendrix, M. J. , Seffor, R.E., Seftor, E.A., Gruman, L.M., Lee, L.M., Nickoloff, B.J., et al. 
(2002).Transendothelial function of human metastatic melanoma cells: role of the 
microenvironment in cell-fate determination. Cancer Res, 62(3), 665-668. 
Bruno, S., Bussolati, B., Grange, C., Collino, F., Graziano, M.E., Ferrando, U., et al. (2006). 
CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol, 
169(6), 2223-2235.   
Kusumbe, A.P., Mali, A.M., & Bapat, S.A. (2009). CD133 expressing stem cells associated 
with ovarian metastases establish an endothelial hierarchy and contribute to tumor 
vasculature. Stem cells, 27(3), 498-508. 
Shen, R., Ye, Y., Chen, L., Yan, Q., Barsky, S.H., & Gao, J.X. (2008). Precancerous stem cells 
can serve as tumor vasculogenic progenitors. PLoS One, 3(2), e1652. 
Chen, L., Shen, R., Ye, Y., Pu, X.A., Liu, X., Duan, W., et al. (2007). Precancerous stem cells have 
the potential for both benign and malignant differentiation. PLoS One, 2(3), e293. 
Bussolati, B., Grange, C., Sapino, A., Camussi, G. (2009). Endothelial cell differentiation of 
human breast tumor stem/progenitor cells. J Cell Mol Med, 13(2), 309-319. 
www.intechopen.com
Cancer Stem Cells Promote Tumor Neovascularization   
 
255 
Bussolati, B., Bruno, S., Gristina, G., Ferrando, U., & Camussi, G. Identification of a tumor-
initiating stem cell population in human renal carcinomas. (2008). FASEB J, 22(10), 
3696-3705. 
Alvero, A.B., Fu, H.H., Holmberg, J., Visintin, I., Mor, L., Marquina, C.C., et al. (2009). Stem-
like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells, 27(10), 
2405-2413. 
Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer., 2007; 7: 
79-94.  
Folberg R, Maniotis AJ. Vasculogenic mimicry. APMIS., 2004; 12(7-8): 508-525.  
Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell 
plasticity: lessons from melanoma. Nat Rev Cancer,, 2003; 3:411-421. 
Sun B, Zhang S, Zhao X, Zhang W, Hao X. Vasculogenic mimicry is associated with poor 
survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. 
Int J Oncol., 2004; 25:1609-1614. 
Van Der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, 
Yokoyama Y, Griffioen AW, Hendrix MJ. Effects of angiogenesis inhibitors on 
vascular network formation by human endothelial and melanoma cells. J Natl 
Cancer Inst., 2004; 96:1473–1477.  
Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug 
Discov., 2007; 6(4): 273-286. 
Gao JX. Cancer stem cells: the lessons from precancerous stem cells. J Cell Mol Med., 2007; 
58: 267-284. 
PezzoloA, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V. Tumor origin of endothelial 
cells in human neuroblastoma. J Clin Oncol., 2007; 25(4): 376-383. 
Shen R, Ye Y, Chen L, Yan QT, Barsky SH, Gao JX. Precancerous stem cells can serve as 
tumor vasculogenic progenitors. PLoS ONE, 2008; 3(2): e1652. 
Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJA. The origin of the cancer stem 
cell: current controversies and new insights. Nat Rev Cancer., 2005; 5:899-904. 
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe’er J, Trent JM, Meltzer PS, 
Hendrix MJC. Vascular channel formation by human melanoma cells in vivo and in 
vitro: vasculogenic mimicry. Am J Pathol., 1999; 155: 739-752. 
Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman 
GC, Seftor RE. Expression and functional significance of VE-cadherin in aggressive 
human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA., 
2001; 98(14): 8018-8023. 
Frenkel S, Barzel I, Levy J, Lin AY, Bartsch DU, Majumdar D, Folberg R, Pe'er J. 
Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by 
confocal indocyanine green angiography. Eye, 2008; 22(7): 948-952. 
Zhang S, Guo H, Zhang D, Zhang W, Zhao X, Ren Z, Sun B. Microcirculation patterns in 
different stages of melanoma growth. Ocol Rep., 2006; 15(1): 15-20. 
Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J 
Pathol., 2000; 156(2):361-381.  
Shirakawa K, Heike Y, Watanabe I, Yanmada S, Saito K, Konishi F. Vasculogenic mimicry 
and pseudo-comedo formation in breast. Int J Cancer., 2002; 99(6):812-828. 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
256 
Sun B, Zhang S, Zhao X, Zhang W, Hao X. Vasculogenic mimicry is associated with poor 
survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. 
Int J Oncol., 2004; 25(6):1609-1614.  
Elzarrad K, Haroon A, Reed D, Al-Mehdi AB. Early incorporated endothelial cells as origin 
of metastatic tumor vasculogenesis. Clin Exp Metastasis., 2009; 26(6): 589-598. 
Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? J Histochem 
Cytochem., 2005; 53(8):997-1002. 
Su M, Feng YJ, Yao LQ, Cheng MJ, Xu CJ, Huang Y, Zhao YQ, Jiang H. Plasticity of ovarian 
cancer cell SKOV3ip and vasculogenic mimicry in vivo. Int J Gynecol Cancer., 2008; 
18(3):476-486.  
Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell 
Melanoma Res., 2008; 21(1):39-55.  
Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med., 2000; 6(4): 389-395.  
Galli R, Binda E, Orfanelli U, Cipelliti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, 
Vescovi A. Isolation and characterization of tumorigenic, stem-like neural 
precursors from human glioblastoma. Cancer Res., 2004; 64(19):7011-7021. 
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano 
MD, Dirks PB. Identification of human brain tumour initiating cells.  Nature, 2004; 
432(7015):396-401. 
D'Amour KA, Gage FH. Genetic and functional differences between multipotent neural and 
pluripotent embryonic stem cells. Proc Natl Acad Sci USA., 2003; 100 (Suppl 1): 
11866-11872. 
Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman 
IL. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature, 
2003; 423(6938): 409-414. 
Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, 
Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank 
MH. Identification of cells initiating human melanomas. Nature, 2008; 451:345-349. 
Bussolati B, Grange C, Sapino A, Camussi G. Endothelial cell differentiation of human 
breast tumor stem/progenitor cells. J Cell Mol Med., 2009; 13(2):309-319. 
Rigolin GM, Fraulini C, Ciccone M, Mauro E, Bugli AM, De Angeli C, Negrini M, Cuneo A, 
Castoldi G. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 
deletion. Blood, 2006; 107(6):2531-2535. 
Medina MA, Munoz-Ch Puli R, Quesada AR. Challenges of antiangiogneic cancer therapy: 
trials and errors, and renewed hope. J Cell Mol Med., 11:378-382. 
Yi L, Zhou ZH, PingYF, Chen JH, Yao XH, Feng H, Lu JY, Wang JM, Bian XW. Isolation and 
characterization of stem cell-like precursor cells from primary human anaplastic 
oligoastrocytoma. Mod Pathol., 2007; 20: 1061–1068. 
Yu SC, Ping YF, Yi L, Zhou ZH, Chen JH, Yao XH, Gao L, Wang JM, Bian XW. Isolation and 
characterization of cancer stem cells from a human glioblastoma cell line U87. 
Cancer Lett., 2008; 265:124-134. 
Elias AP, Dias S. Microenvironment Changes (in pH) Affect VEGF Alternative Splicing. 
Cancer Microenviron., 2008; 1(1):131-139.  
www.intechopen.com
Cancer Stem Cells Promote Tumor Neovascularization   
 
257 
Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, Seftor RE. Remodeling of the 
microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci., 2003; 
995:151-161. 
Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic 
stem cell. Blood Cells, 1978; 4:7-25. 
Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell division in development and 
cancer. Nature, 2006; 441:1068-1074. 
Scadden DT. The stem cell niche as an entity of action. Nature, 2006; 41:1075-1079.  
Vermeulen L, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, 
Stassi G, Medema JP. Single-cell cloning of colon cancer stem cells reveals a multi-
lineage differentiation capacity. Proc Natl Acad Sci USA., 2008; 105(36):13427-
13432. 
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, 
Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff 
A, Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell, 2007; 
11(1):69-82. 
Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK. Functional implication of 
BMP4 expression on angiogenesis in malignant melanoma. Oncogene, 2007; 
26:4158–4170. 
Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, 
Dimeco F, Vescovi AL. Bone morphogenetic proteins inhibit the tumorigenic 
potential of human brain tumour-initiating cells. Nature, 2006; 444:761-765. 
Nakano I, Saigusa K, Kornblum HI. BMPing off glioma stem cells. Cancer Cell, 2008; 13(1):3-4. 
Yao XH, Ping YF, Chen JH, Xu CP, Chen DL, Zhang R, Bian XW. Glioblastoma stem cells 
produce vascular endothelial growth factor by activation of formylpeptide receptor 
(FPR). J Pathol., 2008; 215(4): 369-376. 
Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj RA, Mukherjee P. A 
novel role for cyclooxygenase-2 in regulating vascular channel formation by human 
breast cancer cells. Breast Cancer Res., 2006; 8(6): R69. 
Fujimoto AOH, Mori A, Nagayama S, Yonenaga Y, Tachibana T. Tumor plasticity and 
extravascular circulation in ECV304 human bladder carcinoma cells. Anticancer 
Res., 2006; 26(1A): 59-69. 
Stevens AP, Spangler B, Wallner S, Kreutz M, Dettmer K, Oefner PJ, Bosserhoff AK. Direct 
and tumor microenvironment mediated influences of 5'-deoxy-5'-(methylthio) 
adenosine on tumor progression of malignant melanoma. J Cell Biochem., 2009; 
106(2):210-219. 
Yu SC, Bian XW. Enrichment of cancer stem cells based on heterogeneity of invasiveness. 
Stem Cell Rev., 2009, 5(1): 66-71. 
Hess AR, Seftor EA, Seftor RE, Hendrix MJ. Phosphoinositide 3-kinase regulates membrane 
Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell 
vasculogenic mimicry. Cancer Res., 2003; 63(16):4757-4762. 
Hillen F, Griffoen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer 
Metastasis Rev., 2007; 26:489-502. 
www.intechopen.com
 Cancer Stem Cells Theories and Practice 
 
258 
Borovski, T., Verhoeff, J.J., ten Cate, R., Cameron, K., de Vries, N.A., van Tellingen, O., et al. 
(2009).Tumor microvasculature supports proliferation and expansion of glioma-
propagating cells. Int J Cancer, 125(5), 1222-1230. 
Rak, J., Milsom, C., & Yu, J. (2008). Vascular determinants of cancer stem cell dormancy-do 
age and coagulation system play a role? APMIS, 116(7-8), 660-676. 
Priceman, S.J., Sung, J.L., Shaposhnik, Z., Burton, J.B., Torres-Collado, A.X., Moughon, D.L., 
et al. (2010). Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 
receptor: combating tumor evasion of antiangiogenic therapy. Boold, 115(7), 1461-
1471.  
Koukourakis, M.I., Giatromanolaki, A., Sheldon, H., Buffa, F.M., Kouklakis, G., Ragoussis, I., 
et al. (2009). Phase I/II trial of bevacizumab and radiotherapy for locally advanced 
inoperable colorectal cancer: vasculature-independent radiosensitizing effect of 
bevacizumab. Clin Cancer Res, 15(22), 7069-7076. 
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., et al. (2008). PML 
targeting eradicates quiescent leukaemia-initiating cells. Nature, 453(7198), 1072-
1078.  
www.intechopen.com
Cancer Stem Cells Theories and Practice
Edited by Prof. Stanley Shostak
ISBN 978-953-307-225-8
Hard cover, 442 pages
Publisher InTech
Published online 22, March, 2011
Published in print edition March, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cancer Stem Cells Theories and Practice does not 'boldly go where no one has gone before!' Rather, Cancer
Stem Cells Theories and Practice boldly goes where the cutting edge of research theory meets the concrete
challenges of clinical practice. Cancer Stem Cells Theories and Practice is firmly grounded in the latest results
on cancer stem cells (CSCs) from world-class cancer research laboratories, but its twenty-two chapters also
tease apart cancer's vulnerabilities and identify opportunities for early detection, targeted therapy, and
reducing remission and resistance.
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